Lv3
256 积分 2023-06-12 加入
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
4天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
27天前
已完结
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
1个月前
已完结
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Ponsegromab for the Treatment of Cancer Cachexia
1个月前
已完结
Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS)
2个月前
已完结
Cancer cachexia: understanding the molecular basis
2个月前
已完结
The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL
2个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
5个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
5个月前
已完结
皖公网安备34019202002308
